MXPA05012619A - Inhibicion de la proteina cinasa c-mu como un tratamiento para la hipertrofia cardiaca y la falla cardiaca. - Google Patents
Inhibicion de la proteina cinasa c-mu como un tratamiento para la hipertrofia cardiaca y la falla cardiaca.Info
- Publication number
- MXPA05012619A MXPA05012619A MXPA05012619A MXPA05012619A MXPA05012619A MX PA05012619 A MXPA05012619 A MX PA05012619A MX PA05012619 A MXPA05012619 A MX PA05012619A MX PA05012619 A MXPA05012619 A MX PA05012619A MX PA05012619 A MXPA05012619 A MX PA05012619A
- Authority
- MX
- Mexico
- Prior art keywords
- cardiac hypertrophy
- pkd
- inhibition
- heart failure
- mef
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
Abstract
La presente invencion provee metodos de tratamiento y prevencion de hipertrofia cardiaca y falla cardiaca; se ha mostrado que el MEF-2 y las HDACs de clase II tienen una funcion principal en la hipertrofia cardiaca y al enfermedad del corazon, y se ha mostrado que la inhibicion de HDACs de clase II tiene un efecto benefico antihipertrofico; la presente invencion provee el vinculo entre MEF-2 y HDACs de clase II, una cinasa conocida como PKD; la presente invencion tambien muestra que los inhibidores de PKD inhiben la hipertrofia cardiaca y la enfermedad del corazon inhibiendo en parte la expresion del gen cardiaco fetal y la reorganizacion celular que ocurre cuando se inhibe la transcripcion dependiente de MEF-2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47229803P | 2003-05-21 | 2003-05-21 | |
PCT/US2004/015715 WO2004112763A2 (en) | 2003-05-21 | 2004-05-19 | Inhibition of protein kinase c-mu (pkd) as a treatment for cardiac hypertrophy and heart failure |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05012619A true MXPA05012619A (es) | 2006-02-08 |
Family
ID=33539040
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05012619A MXPA05012619A (es) | 2003-05-21 | 2004-05-19 | Inhibicion de la proteina cinasa c-mu como un tratamiento para la hipertrofia cardiaca y la falla cardiaca. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20050112128A1 (es) |
EP (1) | EP1631268A2 (es) |
JP (1) | JP2007505158A (es) |
CN (1) | CN1812776A (es) |
AU (1) | AU2004249114A1 (es) |
BR (1) | BRPI0410787A (es) |
CA (1) | CA2526423A1 (es) |
MX (1) | MXPA05012619A (es) |
WO (1) | WO2004112763A2 (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005018673A1 (en) * | 2003-08-21 | 2005-03-03 | Osaka University | Pharmaceutical composition for preventing or remedying cardiac hypertrophy and cardiocascular disease caused thereby |
US20090111868A1 (en) * | 2004-12-02 | 2009-04-30 | Marx Steven O | Use Of Rottlerin And Its Derivatives As Activators Of BK Channel For Therapy Of Hypertension And Related Disorders |
WO2007011626A2 (en) | 2005-07-14 | 2007-01-25 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
EP1760092A1 (en) * | 2005-08-26 | 2007-03-07 | Applied Research Systems ARS Holding N.V. | System for screening cells for high expression of a protein of interest |
US20090182003A1 (en) * | 2006-01-13 | 2009-07-16 | President And Fellows Of Harvard College | Methods and Compositions for Treatment Cell Proliferative Disorders |
KR20080108156A (ko) * | 2006-04-06 | 2008-12-11 | 노파르티스 아게 | 유기 화합물의 조합물 |
US9580515B2 (en) * | 2006-08-21 | 2017-02-28 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Neukinase, a downstream protein of neuregulin |
JP2011503103A (ja) * | 2007-11-07 | 2011-01-27 | フォールドアールエックス ファーマシューティカルズ インコーポレーティッド | タンパク質輸送の調節方法 |
GB0810051D0 (en) * | 2008-06-02 | 2008-07-09 | Oxford Biodynamics Ltd | Method of diagnosis |
WO2013053076A1 (en) | 2011-10-10 | 2013-04-18 | Zensun (Shanghai)Science & Technology Limited | Compositions and methods for treating heart failure |
EP2780021A4 (en) * | 2011-11-16 | 2015-08-05 | Univ Duke | BISPHOSPHONATE COMPOSITIONS AND METHODS FOR TREATING AND / OR REDUCING HEART FAILURE |
US9132174B2 (en) | 2013-03-15 | 2015-09-15 | Anchored Rsk3 Inhibitors, Llc | Treatment of heart disease by inhibition of the action of ribosomal S6 kinase 3 (RSK3) |
US10098834B2 (en) | 2013-05-22 | 2018-10-16 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Extended release of neuregulin for treating heart failure |
CN104558110B (zh) * | 2013-10-21 | 2018-06-08 | 中国科学院大连化学物理研究所 | 具有ace抑制活性的多肽及其在降血压药物中的应用 |
CN104558114B (zh) * | 2013-10-21 | 2018-06-08 | 中国科学院大连化学物理研究所 | 花粉中具有ace抑制活性的多肽及其应用 |
CA2932787A1 (en) * | 2013-12-06 | 2015-06-11 | Novimmune S.A. | Anti-tlr4 antibodies and methods of use thereof |
CN110946993A (zh) | 2014-01-03 | 2020-04-03 | 上海泽生科技开发股份有限公司 | 纽兰格林制剂的配方 |
TWI587793B (zh) * | 2014-02-27 | 2017-06-21 | 長庚醫療財團法人基隆長庚紀念醫院 | 改善心臟衰竭症狀的營養組合物 |
GB2527364A (en) * | 2014-06-20 | 2015-12-23 | Imp Innovations Ltd | Treatment |
CN111407882A (zh) | 2014-10-17 | 2020-07-14 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物 |
TN2017000498A1 (en) * | 2015-06-09 | 2019-04-12 | Bayer Pharma AG | Positive allosteric modulators of muscarinic m2 receptor |
WO2019010301A1 (en) * | 2017-07-06 | 2019-01-10 | Kapiloff Michael S | TREATMENT OF CARDIOPATHIES BY INHIBITING THE ACTION OF PROTEINS FROM ANCHORING TO MUSCLE PROTEIN KINASES A (MAKAP) |
CN107811997A (zh) * | 2017-11-10 | 2018-03-20 | 大连医科大学附属第医院 | 蛋白酶体抑制剂白藜芦醇在预防和治疗心血管疾病中的应用 |
CN108379585B (zh) * | 2018-04-16 | 2020-10-16 | 复旦大学附属中山医院 | Hdac4抑制剂在制备治疗心力衰竭的药物中的应用 |
EP3811451A4 (en) * | 2018-05-23 | 2022-04-06 | University of Pittsburgh - of the Commonwealth System of Higher Education | HEART SPECIFIC TARGETING PEPTIDE (CTP), COMPOSITIONS AND USES THEREOF |
EP3852763A1 (en) * | 2018-09-18 | 2021-07-28 | Société des Produits Nestlé S.A. | Src inhibitor compounds for skeletal muscle modulation, methods and uses thereof |
CN109321602B (zh) * | 2018-10-16 | 2021-11-30 | 汉恒生物科技(上海)有限公司 | Pkd2重组过表达载体及其构建方法和用途 |
SG11202112499VA (en) | 2019-05-15 | 2021-12-30 | Univ Miami | Treatment of heart disease by disruption of the anchoring of pp2a |
CN112451529A (zh) * | 2020-12-18 | 2021-03-09 | 忻佑康医药科技(南京)有限公司 | Kb-NB 142-70的药物新用途 |
BR112023023075A2 (pt) * | 2021-05-04 | 2024-01-30 | Enalare Therapeutics Inc | Moduladores de canal de potássio de grande condutância, composições dos mesmos, métodos para fabricar os mesmos e métodos de uso dos mesmos |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4196265A (en) * | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
US4458066A (en) * | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US4873191A (en) * | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
US4415723A (en) * | 1982-03-19 | 1983-11-15 | General Electric Company | Randomly branched aromatic polycarbonate from triphenol |
US5955501A (en) * | 1986-06-11 | 1999-09-21 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators O |
US6080784A (en) * | 1986-06-11 | 2000-06-27 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators N |
US6043270A (en) * | 1986-06-11 | 2000-03-28 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators V |
US4987071A (en) * | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
FR2685346B1 (fr) * | 1991-12-18 | 1994-02-11 | Cis Bio International | Procede de preparation d'arn double-brin, et ses applications. |
TW215434B (es) * | 1992-03-07 | 1993-11-01 | Hoechst Ag | |
US5889136A (en) * | 1995-06-09 | 1999-03-30 | The Regents Of The University Of Colorado | Orthoester protecting groups in RNA synthesis |
WO1997015575A1 (en) * | 1995-10-27 | 1997-05-01 | Procyon Pharmaceuticals, Inc. | Protein kinase c modulators. y. |
US6228843B1 (en) * | 1999-04-23 | 2001-05-08 | University Technology Corporation | Method of using PKC inhibiting compounds to treat vascular disease |
US6372468B1 (en) * | 2000-09-14 | 2002-04-16 | Pe Corporation (Ny) | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
US20030134774A1 (en) * | 2001-06-15 | 2003-07-17 | Steinberg Susan F. | Methods for inhibiting cardiac disorders |
US6706686B2 (en) * | 2001-09-27 | 2004-03-16 | The Regents Of The University Of Colorado | Inhibition of histone deacetylase as a treatment for cardiac hypertrophy |
WO2003075910A1 (en) * | 2002-03-08 | 2003-09-18 | Protemix Corporation Limited | Preventing and/or treating vascular disease, cardiomyopathy and/or associated heart failure |
US20030229030A1 (en) * | 2002-06-11 | 2003-12-11 | Theoharides Theoharis C. | Method of treating interleukin-6-mediated inflammatory diseases |
CN100374158C (zh) * | 2002-08-12 | 2008-03-12 | 密执安州立大学董事会 | 降低细胞atp水平的药剂在制备药物中的应用 |
AU2003214725A1 (en) * | 2002-08-20 | 2004-03-11 | Protemix Corporation Limited | Preventing and/or treating cardiovascular disease and/or associated heart failure |
-
2004
- 2004-05-19 CA CA002526423A patent/CA2526423A1/en not_active Abandoned
- 2004-05-19 WO PCT/US2004/015715 patent/WO2004112763A2/en active Application Filing
- 2004-05-19 MX MXPA05012619A patent/MXPA05012619A/es not_active Application Discontinuation
- 2004-05-19 JP JP2006533221A patent/JP2007505158A/ja active Pending
- 2004-05-19 AU AU2004249114A patent/AU2004249114A1/en not_active Abandoned
- 2004-05-19 US US10/848,820 patent/US20050112128A1/en not_active Abandoned
- 2004-05-19 EP EP04752691A patent/EP1631268A2/en not_active Withdrawn
- 2004-05-19 BR BRPI0410787-0A patent/BRPI0410787A/pt not_active IP Right Cessation
- 2004-05-19 CN CNA2004800139983A patent/CN1812776A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
CN1812776A (zh) | 2006-08-02 |
WO2004112763A3 (en) | 2005-09-09 |
JP2007505158A (ja) | 2007-03-08 |
EP1631268A2 (en) | 2006-03-08 |
AU2004249114A1 (en) | 2004-12-29 |
CA2526423A1 (en) | 2004-12-29 |
BRPI0410787A (pt) | 2006-06-20 |
WO2004112763A2 (en) | 2004-12-29 |
US20050112128A1 (en) | 2005-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA05012619A (es) | Inhibicion de la proteina cinasa c-mu como un tratamiento para la hipertrofia cardiaca y la falla cardiaca. | |
WO2005049084A3 (en) | Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure | |
EA200800006A1 (ru) | Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i | |
GEP20053631B (en) | ) New Spirotricyclic Derivatives and Their Use as Phosphodiesterase-7 Inhibitors | |
PL1748767T3 (pl) | 1-(3-metylo-2,4-dimetoksyfenylo)-3-(2',4'-dihydroksyfenylo)-propan jako silny inhibitor tyrozynazy | |
MXPA04005790A (es) | Compuestos y usos de los mismos para reducir la actividad de la lipasa sensible a la hormona. | |
SG132683A1 (en) | Imidazopyrazine tyrosine kinase inhibitors | |
WO2000061167A3 (en) | TREATMENT OF MYELOMA BONE DISEASE WITH PROTEASOMAL AND NF-λB ACTIVITY INHIBITORS | |
WO2000040235A3 (en) | Treatment of asthma with mek inhibitors | |
MXPA05010958A (es) | Derivados indazol como inhibidores jnk. | |
HK1057899A1 (en) | Arylmethylamine derivatives for use as tryptase inhibitors | |
NZ515567A (en) | Method for treating chronic pain using MEK inhibitors | |
WO2005000213A8 (en) | Method for treating diseases using hsp90-inhibiting agents in combination with enzyme inhibitors | |
SG149027A1 (en) | Substituted urea derivatives for treating cardiac diseases | |
HK1087702A1 (en) | Arylmethylamine derivatives for use as tryptase inhibitors | |
WO2007014033A3 (en) | Inhibition of extracellular signal-regulated kinase 1/2 as a treatment for cardiac hypertrophy and heart failure | |
EA200100804A1 (ru) | Сульфоароматические производные гидроксамовой кислоты как ингибиторы металлопротеаз | |
WO2003024386A8 (en) | Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis | |
DE60137635D1 (de) | Verwendung von allopurinol zur behandlung von bluthochdruck | |
WO2003092606A3 (en) | Cholinesterase inhibitors to prevent injuries caused by chemicals | |
ATE478142T1 (de) | Behandlung von melanomen durch reduktion der clusterin menge | |
WO2005016327A3 (en) | Treatment of sleep disorders with cholinesterase inhibitors | |
TW200503666A (en) | Treatment of type 1 diabetes with pde5 inhibitors | |
WO2003037308A3 (de) | Verwendung von inhibitoren der rho-kinasen zur stimulation des nervenwachstums | |
WO2003094967A3 (en) | New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |